

A close-up photograph of a woman with long blonde hair hugging a young girl with dark hair. The woman is wearing a beige knitted sweater and a large silver ring. The girl is wearing a white shirt with small yellow flowers. The background is blurred, showing a plant and a wall.

# Nobelpharma

**Nobelpharma develops medications and medical devices for underserved patient populations.**

Visit us at [nobelpharma-us.com](https://nobelpharma-us.com) for more information about our mission and approach to product development.

# A Leader in Scientific Advancement

## Who We Are

Nobelpharma America, LLC is the first global subsidiary of Nobelpharma Co., Ltd., headquartered in Tokyo, Japan. Nobelpharma develops critical but neglected pharmaceuticals and medical devices.

Our company name comes from Alfred Nobel, the founder of the Nobel Prize. We are proud to be part of Alfred Nobel's innovative and scientific legacy. His groundbreaking achievements continue to inspire our company's mission and values.



## Priorities

Nobelpharma is committed to meeting essential patient needs by developing treatments for diseases that often go overlooked because of the small number of patients affected.

No one should have to experience the anxiety and vulnerability that comes with a condition that can be difficult to treat or manage.

## Our Leadership

### U.S. Leadership

**“We are excited about the possibility of extending Nobelpharma’s reach to U.S. patients, carrying on Alfred Nobel’s tradition of scientific advancement and innovation.”**

Yoshiki Kida, President & CEO of Nobelpharma America, LLC



### Global Leadership

**“Nobelpharma’s commitment to patients across the world is a clear push to serve underserved patient communities.”**

Jin Shiomura, President & CEO of Nobelpharma Co., Ltd.




# Patients First

Nobelpharma's unique "patients first" approach to product development targets medical conditions that have limited or no treatment options or may go overlooked because of the small number of patients affected.

We aspire to provide hope to families who live with conditions such as facial angiofibroma associated with tuberous sclerosis complex (TSC). We are committed to working closely with groups like the TSC Alliance to help improve the lives of people living with diseases that have limited treatment options.



## Timeline of Success



# Research and Development

Through an efficient and robust R&D process, we strive to bring innovative products to market as quickly as possible, hoping to provide patients and physicians with treatment options for underserved patient populations.

The Nobelpharma America pipeline includes potential treatments for conditions that have little or no other treatment options in the U.S.

## Facial angiofibroma associated with tuberous sclerosis complex (TSC)

Sirolimus topical gel 0.2% (NPC-12G)\* is a topical mTOR inhibitor, currently under review with the U.S. Food and Drug Administration (FDA) with a target indication for facial angiofibroma associated with TSC. The FDA has not yet made a determination as to the safety and effectiveness of this product for the target indication.

Tuberous sclerosis complex (TSC) is an autosomal dominant genetic rare disease that causes benign tumors on the skin and vital organs (including brain, kidney, lung, and heart) and may result in behavioral manifestations such as autism, intellectual disability, and neurologic epilepsy symptoms.

Facial angiofibroma associated with TSC is a facial skin lesion and hamartoma caused by aberrant activation of the mechanistic target of rapamycin (mTOR) inhibitor. Without treatment, these may cause significant disfigurement, bleeding, pruritus, and erythema.

Nobelpharma received approval in Japan (2018)\*

## Tympanic membrane perforation (TMP)

(NPC-18)\* is a drug approved in Japan for the treatment of **tympanic membrane perforation**.

Nobelpharma received approval in Japan (2019)\*

## Adductor spasmodic dysphonia

(NPC-17)\* is a medical device approved in Japan for type II thyroplasty for the treatment of **adductor spasmodic dysphonia**.

Nobelpharma received approval in Japan (2018)\*

In addition to 15 drugs and devices approved in Japan, Nobelpharma has another seven products currently in R&D. Nobelpharma hopes to bring many of these products to the U.S. in the future.

\* Nobelpharma products are approved in Japan, and have not been approved or deemed safe and effective by the FDA, and are not available for commercial sale in the U.S. NPC-18 and NPC-17 are investigational only in the U.S.

This document contains information about products that may not be available in the U.S. Nothing contained herein should be considered a solicitation, promotion, or advertisement for any product including those under development.

**Nobelpharma America, LLC**  
4520 East-West Highway  
Suite 400, Bethesda, MD 20814  
**301-244-5951**

 [nobelpharma-us.com](http://nobelpharma-us.com)

 [@NobelpharmaUS](https://twitter.com/NobelpharmaUS)

 Nobelpharma America, LLC